From the Journals

Early cardiac rehab as effective as later start after sternotomy


 

FROM JAMA CARDIOLOGY

Questions remain

Asked to comment on the study, John Larry, MD, medical director of cardiology and cardiac rehabilitation at the Ohio State University Wexner Medical Center East Hospital, Columbus, said: “For those under time pressure to return to work, [early CR] could be an advantage to allow more rehab time and improved stamina prior to their return-to-work date.”

That said, he noted, “we typically delay any significant upper-body training activities for 8-10 weeks to avoid impact on healing of the sternum. Thus ... starting sooner would limit the amount of time a patient would have to engage in any upper-body resistance training. Many lose upper body strength after surgery, so this is an important part of the recovery/rehab process.”

Matthew Tomey, MD, director of the cardiac intensive care unit, Mount Sinai Morningside, New York, advised “caution” when interpreting the findings, stating that “there was no evident difference in the primary outcome measure of functional capacity by 14 weeks, and the trial was not designed to directly assess impact on either social functioning or economic productivity.”

“I would be interested to [see] more comprehensive data on safety in a larger, more diverse sample of postoperative patients,” he said, “as well as evidence to indicate clear advantage of an earlier start for patient-centered outcomes specifically after cardiac surgery.

“Perhaps the greatest challenges to full realization of the benefits of CR in practice have been gaps in referral and gaps in enrollment,” he added. “It is incumbent upon us as clinicians to counsel our patients and to provide appropriate referrals.”

The study was supported by the Medical and Life Sciences Research Fund and the Jeremy Pilcher Memorial Fund. No conflicts of interest were reported.

A version of this article first appeared on Medscape.com.

Pages

Recommended Reading

Empagliflozin rapidly improves acute heart failure symptoms in hospitalized patients
MDedge Family Medicine
Icosapent ethyl’s CV mortality benefit magnified in patients with prior MI
MDedge Family Medicine
Will you have cardiac arrest? New tech may predict if and when
MDedge Family Medicine
FDA clears mavacamten (Camzyos) for obstructive hypertrophic cardiomyopathy
MDedge Family Medicine
Cutting dementia risk in AFib: Does rhythm control strategy matter?
MDedge Family Medicine
Porcine virus a suspect in man’s death after pig heart transplant
MDedge Family Medicine
Path to parenthood in cardiology training fraught with obstacles
MDedge Family Medicine
New guideline for in-hospital care of diabetes says use CGMs
MDedge Family Medicine
Cause of death in pig heart recipient: New clues
MDedge Family Medicine
Meta-analysis points to safety of acetylcholine coronary testing
MDedge Family Medicine